Hologic, Inc. (HOLX) Expected to Announce Earnings of $0.59 Per Share

Equities analysts expect Hologic, Inc. (NASDAQ:HOLX) to announce earnings of $0.59 per share for the current quarter, Zacks reports. Eight analysts have made estimates for Hologic’s earnings, with the highest EPS estimate coming in at $0.60 and the lowest estimate coming in at $0.57. Hologic reported earnings per share of $0.50 in the same quarter last year, which would suggest a positive year-over-year growth rate of 18%. The business is expected to issue its next quarterly earnings report after the market closes on Wednesday, November 7th.

On average, analysts expect that Hologic will report full-year earnings of $2.24 per share for the current year, with EPS estimates ranging from $2.22 to $2.25. For the next year, analysts anticipate that the firm will post earnings of $2.41 per share, with EPS estimates ranging from $2.34 to $2.58. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that follow Hologic.

Hologic (NASDAQ:HOLX) last released its earnings results on Tuesday, July 31st. The medical equipment provider reported $0.58 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.56 by $0.02. The firm had revenue of $824.00 million during the quarter, compared to analysts’ expectations of $800.14 million. Hologic had a negative net margin of 2.47% and a positive return on equity of 22.18%.

Several research firms recently commented on HOLX. Needham & Company LLC upped their target price on shares of Hologic from $43.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, August 1st. BidaskClub raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Wednesday, August 1st. Deutsche Bank boosted their price target on shares of Hologic from $42.00 to $45.00 and gave the company a “hold” rating in a report on Wednesday, August 1st. Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Finally, Bank of America boosted their price target on shares of Hologic from $44.00 to $47.00 and gave the company a “buy” rating in a report on Wednesday, August 1st. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $44.47.

In other news, Director Christiana Stamoulis sold 30,967 shares of the company’s stock in a transaction dated Tuesday, October 2nd. The shares were sold at an average price of $40.70, for a total value of $1,260,356.90. Following the sale, the director now owns 66,006 shares of the company’s stock, valued at approximately $2,686,444.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Benjamin Jordan Cohn sold 3,437 shares of the company’s stock in a transaction dated Wednesday, September 19th. The stock was sold at an average price of $41.50, for a total transaction of $142,635.50. Following the completion of the sale, the insider now directly owns 16,520 shares in the company, valued at approximately $685,580. The disclosure for this sale can be found here. In the last ninety days, insiders sold 47,661 shares of company stock worth $1,927,174. 0.88% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of HOLX. Sentry Investment Management LLC grew its holdings in Hologic by 8.3% during the 2nd quarter. Sentry Investment Management LLC now owns 18,271 shares of the medical equipment provider’s stock worth $726,000 after acquiring an additional 1,394 shares during the last quarter. CIBC Asset Management Inc grew its holdings in Hologic by 4.1% during the 2nd quarter. CIBC Asset Management Inc now owns 38,603 shares of the medical equipment provider’s stock worth $1,534,000 after acquiring an additional 1,504 shares during the last quarter. Jane Street Group LLC grew its holdings in Hologic by 30.3% during the 1st quarter. Jane Street Group LLC now owns 6,904 shares of the medical equipment provider’s stock worth $258,000 after acquiring an additional 1,607 shares during the last quarter. United Capital Financial Advisers LLC grew its holdings in Hologic by 34.4% during the 1st quarter. United Capital Financial Advisers LLC now owns 6,395 shares of the medical equipment provider’s stock worth $239,000 after acquiring an additional 1,638 shares during the last quarter. Finally, Amalgamated Bank grew its holdings in Hologic by 4.6% during the 1st quarter. Amalgamated Bank now owns 37,694 shares of the medical equipment provider’s stock worth $1,408,000 after acquiring an additional 1,674 shares during the last quarter. 98.65% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:HOLX traded up $0.70 during trading hours on Monday, hitting $40.04. 2,086,350 shares of the company traded hands, compared to its average volume of 2,324,738. The stock has a market cap of $11.15 billion, a P/E ratio of 19.72, a PEG ratio of 2.01 and a beta of 0.67. Hologic has a twelve month low of $35.10 and a twelve month high of $45.09. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.29 and a quick ratio of 0.99.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

See Also: Using the New Google Finance Tool

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply